Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization - PubMed (original) (raw)
Review
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization
J-L Raoul et al. Cancer Treat Rev. 2011 May.
Abstract
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, intermediate-stage HCC includes a heterogeneous population of patients with varying tumour burdens, liver function (Child-Pugh A or B) and disease aetiology. This suggests that not all patients with intermediate-stage HCC will derive similar benefit from TACE, and that some patients may benefit from other treatment options. Results of an extensive literature review into the treatment of unresectable HCC with TACE were combined with our own clinical experience to identify factors that may predict survival after TACE. We also report contraindications to TACE and propose a treatment algorithm for the repetition of TACE. In addition, we have constructed a number of expert opinions that may be used as a guide to help physicians make treatment decisions for their patients with intermediate-stage HCC. The data included in the literature review related almost exclusively to conventional TACE, rather than to TACE with drug-eluting beads. Therefore, the findings and conclusions of the literature review are only applicable to the treatment of HCC with conventional TACE. Treating physicians may want to consider other treatment options for patients with intermediate-stage HCC who are not suitable for or do not respond to TACE. By distinguishing those patients who represent good candidates for TACE from those where little or no benefit might be expected, it may be possible to make better use of current treatment options and improve outcomes for patients.
Copyright © 2010. Published by Elsevier Ltd.
Similar articles
- Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Choi JY. Choi JY. Oncology. 2011;81 Suppl 1:141-7. doi: 10.1159/000333277. Epub 2011 Dec 22. Oncology. 2011. PMID: 22212948 - Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).
Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Dhanasekaran R, et al. J Surg Oncol. 2010 May 1;101(6):476-80. doi: 10.1002/jso.21522. J Surg Oncol. 2010. PMID: 20213741 - Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.
Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P, Cheng AL. Han KH, et al. Oncology. 2011;81 Suppl 1:158-64. doi: 10.1159/000333280. Epub 2011 Dec 22. Oncology. 2011. PMID: 22212951 - Chemoembolization of hepatocellular carcinoma--what to tell the skeptics: review and meta-analysis.
Ramsey DE, Geschwind JF. Ramsey DE, et al. Tech Vasc Interv Radiol. 2002 Sep;5(3):122-6. doi: 10.1053/tvir.2002.36418. Tech Vasc Interv Radiol. 2002. PMID: 12524642 Review.
Cited by
- Antitumor properties of arsenic trioxide-loaded CalliSpheres® microspheres by transarterial chemoembolization in VX2 liver tumor rabbits: suppression of tumor growth, angiogenesis, and metastasis and elongation of survival.
Duan X, Li H, Han X, Ren J, Li F, Ju S, Wang M, Wang W. Duan X, et al. Am J Transl Res. 2020 Sep 15;12(9):5511-5524. eCollection 2020. Am J Transl Res. 2020. PMID: 33042434 Free PMC article. - Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients.
Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M. Facciorusso A, et al. World J Hepatol. 2015 Aug 8;7(16):2009-19. doi: 10.4254/wjh.v7.i16.2009. World J Hepatol. 2015. PMID: 26261690 Free PMC article. Review. - Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs.
Mullick Chowdhury S, Wang TY, Bachawal S, Devulapally R, Choe JW, Abou Elkacem L, Yakub BK, Wang DS, Tian L, Paulmurugan R, Willmann JK. Mullick Chowdhury S, et al. J Control Release. 2016 Sep 28;238:272-280. doi: 10.1016/j.jconrel.2016.08.005. Epub 2016 Aug 5. J Control Release. 2016. PMID: 27503707 Free PMC article. - Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.
Wang L, Wang H, Cui Y, Liu M, Jin K, Xu D, Wang K, Xing B. Wang L, et al. Front Oncol. 2023 Feb 16;13:1115109. doi: 10.3389/fonc.2023.1115109. eCollection 2023. Front Oncol. 2023. PMID: 36874115 Free PMC article. - Myeloid-derived suppressor cells in the patients with liver resection for hepatitis B virus-related hepatocellular carcinoma.
Lee WC, Wang YC, Cheng CH, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM. Lee WC, et al. Sci Rep. 2019 Feb 19;9(1):2269. doi: 10.1038/s41598-019-38785-3. Sci Rep. 2019. PMID: 30783140 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous